WUHAN YZY BIOPHARMA CO., LTD.

Highlights Wuhan YZY Biopharma Co., Ltd.

Equities

2496

CNE1000063C4

Market Closed - Hong Kong S.E. Other stock markets 09:08:12 14/06/2024 BST			5-day change	1st Jan Change
7.48 ^HKD	0.00%		+0.40%	-15.96%

05-24	Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference	MT
05-24	Wuhan YZY Biopharma Co., Ltd. Announces Phase II Study Data of M701 for the Treatment of Malignant Ascites Presented At the 2024 ASCO Meeting	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference	05-24	MT
Wuhan YZY Biopharma Co., Ltd. Announces Phase II Study Data of M701 for the Treatment of Malignant Ascites Presented At the 2024 ASCO Meeting	05-24	CI
Wuhan YZY Biopharma Co., Ltd. Announces the First Patient Enrolled in Phase III Clinical Trial of M701	03-27	CI
Wuhan YZY Biopharma Co., Ltd. Announces the First Patient Has Recently Been Enrolled in A Phase Ii Clinical Trial of M701	03-26	CI
Wuhan YZY Biopharma Discloses Partial Exercise of IPO's Over-Allotment; Shares Slump 15%	19/10/23	MT
Wuhan YZY Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
China Evergrande Debt Troubles Drag Hong Kong Stocks; Wuhan YZY Biopharma Closes Flat, LC Logistics Slip in Debut	25/09/23	MT
Wuhan YZY Biopharma Raises HK$121 Million in Hong Kong IPO, Prices at Bottom of Range	22/09/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW